SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as investors focus on its decentralized GPU compute network and a revenue-sharing model that rewards stakers and node runners with real earnings. The community is actively discussing a potential supply shock, driven by the fact that a significant majority of the token supply is currently locked in long-term staking.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is surging as a core beneficiary of the Nasdaq-100 rebalance, with the community highlighting its essential role as a testing "tollbooth" for the AI infrastructure supply chain. Investors are actively debating the stock's long-term valuation against other AI hardware leaders, noting that the index inclusion provides a structural catalyst for passive institutional demand.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a major point of contention as investors debate whether the token's significant price decline represents a rare accumulation opportunity for high-utility infrastructure or a long-term value trap. While many community members are frustrated by the lack of price momentum compared to other altcoins, others are doubling down, citing its active role in institutional real-world asset tokenization and enterprise adoption as evidence that the technology remains disconnected from its current market valuation.

Vishay Intertechnology, Inc. engages in the manufacture and distribution of discrete semiconductors and passive electronic components. It operates through the following segments: MOSFET (metal oxide semiconductor field-effect transistor), Diodes, Optoelectronic Components, Resistors, Inductors, and Capacitors. The MOSFET segment offers semiconductors which function as solid state switches to control power. The Diodes segment produces semiconductors which route, regulate, and block radio frequency, analog, and power signals, protect systems from surges or electrostatic discharge damage, and provide electromagnetic interference filtering. The Optoelectronic Components segment includes components that emit light, detect light, or do both. The Resistors and Inductors segment deals with components that impede electric current. The Capacitors segment provides components which store energy and discharge it when needed. The company was founded by Felix Zandman in 1962 and is headquartered in Malvern, PA.

Vishay Intertechnology, Inc.

Vishay Intertechnology is seeing intense institutional interest following a series of breakouts to fresh highs, with community discourse centered on its role as a critical supplier for semiconductor tooling and AI infrastructure. Investors are actively monitoring the stock's resilient technical structure and the broader thematic rotation into high-beta physical-layer leaders.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending as market participants closely monitor escalating geopolitical tensions surrounding the Strait of Hormuz and persistent uncertainty over U.S.-Iran diplomatic negotiations. The community is actively debating the durability of supply constraints, with many traders focused on how potential ceasefires or further military escalation will influence crude oil price volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is experiencing heightened interest as investors shift focus toward potential mergers, acquisitions, and positive clinical trial readouts within the sector. Community sentiment is driven by a mix of optimism over sector rotation, strategic buying during pullbacks, and speculative excitement surrounding individual biotech firms that are gaining regulatory momentum.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as investors gear up for quarterly earnings, fueled by significant insider buying from the CEO and strong momentum in the digital health sector. The community is actively debating the stock's recent rapid appreciation, balancing bullish enthusiasm for the company's membership growth and platform efficiency against concerns regarding valuation sustainability and volatility following a massive year-to-date run.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is capturing investor attention following its recent listings on major exchanges, driving speculation around its role in the real-world asset sector and its application in decentralized reinsurance markets. The community is actively debating the token's long-term utility, monitoring its ability to hold support levels, and analyzing the impact of its limited circulating supply.

Gitlawb is a decentralized code collaboration platform designed for AI agents and human developers. It provides a Git-compatible hosting layer where repositories are stored across IPFS, Filecoin, and Arweave, and peer connectivity is handled through libp2p rather than a central server.  Identity on Gitlawb is based on decentralized identifiers (DIDs) using Ed25519 keys. Access control and delegation between users and agents are expressed as UCAN (User Controlled Authorization Networks) capabilities, allowing scoped, revocable permissions to be granted without a central authority. Each identity carries an on-chain trust score derived from verified contributions.  The protocol is accessed through three main surfaces: a Rust node (gitlawb-node) that serves repositories over HTTP and libp2p, a command-line client (gl) that handles identity, repositories, issues, bounties, and UCAN delegation, and a git remote helper (git-remote-gitlawb) that allows standard Git clients to push and pull using gitlawb:// URLs.  Additional products in the ecosystem include MiroClaw, an on-chain prediction market; Gitlawb Spawn, an AI agent orchestration tool; OpenClaude, an open-source agent harness aligned with Playground and Spawn; and a developer playground for testing agent interactions against the protocol.

Gitlawb

Gitlawb is trending as investors rally behind its vision as a decentralized, AI-native infrastructure for autonomous agents to own and manage code. The community is actively discussing the project's utility-focused tokenomics, including supply reduction plans, alongside potential exchange listings and strategic partnerships in the broader AI-crypto space.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is gaining traction as investors focus on resilient premium travel demand and optimistic revenue guidance, even as the sector faces significant margin pressures from elevated jet fuel costs tied to geopolitical volatility in the Middle East. The community is actively debating the sustainability of these price increases, with many closely monitoring how capacity adjustments and refinery hedging strategies will impact bottom-line profitability during the upcoming earnings season.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Equity

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.


Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.


Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.


Macy's, Abercrombie and Moderna fall premarket; Sage soars

Investing.com -- US stock futures fell Monday, as investors fretted that the hot jobs report will prompt the Federal Reserve to hold back on rate cuts this year.

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sage Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.68
Prev Close	$8.70
Open	$8.74
Dividend Yield	0.00%
50-Day Moving Average	$8.44
Beta	1.07
Avg. Volume	3.55M
PE Ratio	-1.77

52-Week High	$9.36
52-Week Low	$4.62
Market Capitalization	$543.64M
EPS (Annual)	-$6.59
Price to Book	1.47
Revenue Per Employee	$116,835.69

SAGESage Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAGE News